### **Balaxi** Pharmaceuticals Limited

То

8th November, 2021

Listing Department, National Stock Exchange of India Limited. Exchange Plaza, Plot No C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai-400051

Stock Code: BALAXI

Sub: Update on acquisition of Step-down Subsidiary

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Balaxi Global DMCC, Dubai ("BGD"), Wholly Owned Subsidiary of the Company has completed acquisition of 99% shares of Balaxi Healthcare El Salvador, S.A DE C.V, El Salvador, Central America ("BHES") as informed by the Subsidiary, which has consequently become the Step-down subsidiary of Balaxi Pharmaceuticals Limited.

The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated 9<sup>th</sup> September 2015, are given in Annexure-A.

We request you to kindly take this on record.

Yours Faithfully, For **Balaxi Pharmaceuticals Limited** 

C. Slel CEL Chinta Shalini lyderaba **Company Secretary** 

Registered Office: 2<sup>nd</sup> Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096. CIN: L25191TG1942PLC121598 Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in (Formerly known as Balaxi Ventures Limited)

# **Balaxi** Pharmaceuticals Limited

#### Annexure A

Sl. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	Balaxi Healthcare El Salvador, S.A DE C.V ("BHES") is a step-down subsidiary of Balaxi Pharmaceuticals Limited
		Turnover, Size: NIL
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired	Yes, the acquisition falls under the definition of related party transaction and the transaction was done at arm's length basis.
		The Shares of the acquired Company were sold by Ashish Maheshwari who is the Managing Director and Promoter Group of Balaxi Pharmaceuticals Limited.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals Distribution Company
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Balaxi Healthcare El Salvador, S.A DE C.V is engaged in Balaxi's pharmaceutical formulation products in El Salvador. The above said activity is in line with the main objects of this parent listed entity
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable
6.	Indicative time period for completion of the acquisition	The acquisition was completed on 8 <sup>th</sup> November, 2021
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Consideration in Cash
8.	Cost of acquisition or the price at which the shares are acquired	USD 2,000

#### **Registered Office:**

2<sup>nd</sup> Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096. CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 Email: info@balaxi.in Website: www.balaxipharma.in

(Formerly known as Balaxi Ventures Limited)

## **Balaxi** Pharmaceuticals Limited

9.	Percentage of shareholding / control acquired and / or number of shares acquired	Balaxi Global DMCC shall hold 99% shares of BHES
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover,	Date of incorporation: 28 <sup>th</sup> September, 2015
	country in which the acquired entity has presence and any other significant information (in brief);	<b>Country of incorporation:</b> El Salvador
		Turnover: NIL

2<sup>nd</sup> Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096. CIN: L25191TG1942PLC121598 Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in (Formerly known as Balaxi Ventures Limited)

**Registered Office:**